news-details
Health,Watchlist,healthcare stocks

6 HealthTech Stocks Trending Now ARVN stock, CRBU stock, LLY stock, SGRY stock, IMGO stock, ENTA stock

Powered by healthtechmovers.com

According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist.  That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..

Arvinas Holding Company, ARVN
Recent ARVN Stock Price: $39.56
Summary:
Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

Etzer Darout analyst at BMO Capital reiterates coverage on Arvinas Holding Company (ARVN) stock in the energy sector with a Buy rating and has set ARVN's stock price target at $ 95.

TipRanks.com reports that Arvinas Holding Company currently has n/a analysts offering 12-month price targets on ARVN and the consensus is a Strong Buy rating with an average stock price target of n/a.  The most recent ARVN stock price we have is $39.56 and we are not making any ARVN forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for ARVN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on ARVN, please click here >>

Caribou Biosciences, CRBU
Recent CRBU Stock Price: $8.79
Summary:
Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.

Yigal Nochomovitz analyst at Citigroup reiterates coverage on Caribou Biosciences (CRBU) stock in the energy sector with a Buy rating and has set CRBU's stock price target at $ 37.

TipRanks.com reports that Caribou Biosciences currently has 6 analysts offering 12-month price targets on CRBU and the consensus is a Strong Buy rating with an average stock price target of $27.17.  The most recent CRBU stock price we have is $8.79 and we are not making any CRBU forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for CRBU over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CRBU. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on CRBU, please click here >>

Eli Lilly & Co, LLY
Recent LLY Stock Price: $361.72
Summary:
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Kerry Holford analyst at Berenberg Bank reiterates coverage on Eli Lilly & Co (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $ 375.

TipRanks.com reports that Eli Lilly & Co currently has 15 analysts offering 12-month price targets on LLY and the consensus is a Strong Buy rating with an average stock price target of $382.71.  The most recent LLY stock price we have is $361.72 and we are not making any LLY forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for LLY over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on LLY, please click here >>

Surgery Partners, SGRY
Recent SGRY Stock Price: $27.49
Summary:
Surgery Partners, Inc. is a healthcare services company. The Company's outpatient delivery model focused on providing solutions for surgical and related ancillary care in support of its patients and physicians. Its operating segment consists of Surgical Facility Services segment, Ancillary Services segment and Optical Services segment. Surgery Partners, Inc. is based in Nashville, Tennessee.

Lisa Gill analyst at J.P. Morgan reiterates coverage on Surgery Partners (SGRY) stock in the energy sector with a Hold rating and has set SGRY's stock price target at $ 45.

TipRanks.com reports that Surgery Partners currently has 6 analysts offering 12-month price targets on SGRY and the consensus is a Moderate Buy rating with an average stock price target of $40.33.  The most recent SGRY stock price we have is $27.49 and we are not making any SGRY forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for SGRY over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SGRY. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on SGRY, please click here >>

Imago BioSciences, IMGO
Recent IMGO Stock Price: $35.64
Summary:
Imago BioSciences Inc. is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc. is based in SOUTH SAN FRANCISCO, Calif.

Mitchell Kapoor analyst at H.C. Wainwright reiterates coverage on Imago BioSciences (IMGO) stock in the energy sector with a Hold rating and has set IMGO's stock price target at $ 36.

TipRanks.com reports that Imago BioSciences currently has 4 analysts offering 12-month price targets on IMGO and the consensus is a Hold rating with an average stock price target of $36.00.  The most recent IMGO stock price we have is $35.64 and we are not making any IMGO forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for IMGO over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMGO. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on IMGO, please click here >>

Enanta Pharmaceuticals, ENTA
Recent ENTA Stock Price: $45
Summary:
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.

Brian Abrahams analyst at RBC Capital reiterates coverage on Enanta Pharmaceuticals (ENTA) stock in the energy sector with a Hold rating and has set ENTA's stock price target at $ 54.

TipRanks.com reports that Enanta Pharmaceuticals currently has 5 analysts offering 12-month price targets on ENTA and the consensus is a Moderate Buy rating with an average stock price target of $75.40.  The most recent ENTA stock price we have is $45 and we are not making any ENTA forecasts at this time.

In addition, TradingView issued a n/a (possibly response change) rating for ENTA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ENTA. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.

For the complete breakdown on ENTA, please click here >>



The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports.  One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================